India, Aug. 27 -- September 2025 could be a make-or-break month for some biotech stocks, as the companies prepare to release critical clinical trial data.
The following are some of the biotech stocks to watch in September, with potential catalysts that may drive major market moves.
KALA BIO Inc. (KALA)
KALA is expected to release topline data from its CHASE trial of KPI-012 by the end of September 2025.
CHASE is a Phase 2b trial evaluating lead investigational topical biologic therapy, KPI-012, for the treatment of persistent corneal epithelial defect.
Persistent corneal epithelial defect is a rare, non-healing corneal defect or wound that is refractory to conventional treatments, often leading to corneal ulceration, perforation, strom...